GlassScriptPhysician profile
Sandra Lee Weber
NPI 1821039041
$4,810.09
in general payments reported to CMS, 2019-2025
37 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $105 · 2021: $201 · 2022: $692 · 2023: $915 · 2024: $751 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645 · Gift: $59.40 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.55 |
| Gift | $59.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $518.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $481.08 | 2019-2025 | Omnipod |
| Abbott Laboratories | $379.11 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $282.59 | 2022-2023 | Minimed 780g |
| Lilly USA, LLC | $281.92 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $268.59 | 2022-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $231.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.17 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $218.02 | 2019-2024 | Korlym |
| Ascensia Diabetes Care US INC. | $214.61 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $161.79 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $150.76 | 2019-2025 | Evenity, Tepezza |
| Sanofi-Aventis U.S. LLC | $143.46 | 2019-2024 | |
| Mannkind Corporation | $123.35 | 2019-2023 | Afrezza |
| Amarin Pharma, INC. | $104.79 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $104.26 | 2019 | |
| Tandem Diabetes Care, INC. | $101.46 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $88.03 | 2019-2025 | Synthroid |
| Pfizer INC. | $71.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $68.89 | 2024-2025 | |
| Madrigal Pharmaceuticals | $55.66 | 2025 | Rezdiffra |
| Cequr Corporation | $53.13 | 2022-2024 | Cequr Simplicity |
| Intuity Medical INC | $51.45 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amneal Pharmaceuticals LLC | $51.22 | 2019-2020 | |
| Chiesi USA, INC. | $49.01 | 2025 | Mycapssa |
| Radius Health, INC. | $48.95 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $48.26 | 2022 | |
| Embecta Corp. | $43.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Becton, Dickinson and Company | $34.63 | 2019 | |
| Lifescan, INC. | $33.57 | 2020-2023 | |
| Antares Pharma, INC. | $32.75 | 2019-2025 | Xyosted |
| Sequel Med Tech, LLC | $21.63 | 2025 | Twiist |
| Shire North American Group INC | $19.78 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.21 | 2021 | |
| Recordati_rare_diseases_inc. | $17.73 | 2024 | Signifor Lar, Isturisa |
| Tolmar, INC. | $14.58 | 2025 | Jatenzo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.